The peptide combinations (“stacks”) most often promoted in clinic ads, social media, and online retailer copy — mapped against what the published evidence actually shows, what is missing, and where the regulatory line sits.
Previously this page let you select two or three peptides and returned a synergy score and protocol suggestion. We removed it because (a) the underlying combinations have, in nearly every case, no published RCT data in humans; (b) producing a confident synergy/safety output from absent evidence is misleading; (c) the tool incentivised treating unlicensed substances as a menu rather than as research compounds. The reviews below replace it: each claimed combination is named, the evidence base is summarised honestly, and the unknowns are made explicit.
Marketing pitch: ““The healing stack”. Routinely sold as a synergistic injury-recovery combination.”
Both compounds are unlicensed in the UK and EU. Each has a preclinical literature for tissue repair in isolation. There are no human RCTs of the combination. Synergy is asserted in marketing, not demonstrated in published controlled studies in humans.
Read the full claim reviewMarketing pitch: ““GH-pulse stack” for body recomposition and sleep.”
Both are growth-hormone-releasing peptides; combined, they produce a larger and more sustained GH pulse than either alone. Short-term pharmacokinetics are characterised in research literature. Long-term safety in non-deficient adults is not established; both are unlicensed in the UK.
Read the full claim reviewMarketing pitch: “Combine GLP-1 weight loss with ‘targeted’ fat metabolism.”
Semaglutide is a licensed GLP-1 receptor agonist (Wegovy, Ozempic) with substantial trial data. AOD-9604 is an unlicensed fragment with no published combination data in humans. The combination is not studied in any registered RCT. Stacking an unlicensed substance with a prescription medicine creates legal and clinical risk (“polypharmacy with one unknown”).
Read the full claim reviewMarketing pitch: “Tan and libido in one stack.”
Melanotan II is unlicensed and associated with documented adverse events in MHRA advisories (skin lesions, mole changes, GI effects). PT-141 (bremelanotide) is licensed in the US for HSDD in pre-menopausal women but not in the UK. Combination is not studied. The MHRA has repeatedly warned against Melanotan II.
Read the full claim review